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Thoracic aortic dilation (AD) has commonly been described in conotruncal defects 
(CTDs), such as tetralogy of Fallot, double outlet right ventricle and transposition of the 
great arteries, and truncus arteriosus. Several theories for this have been devised, but 
fairly recent data indicate that there is likely an underlying histologic abnormality, similar 
to that seen in Marfan and other connective tissue disease. The majority of aortic dis-
section in the general population occurs after the age of 45 years, and there have been 
very few case reports of aortic dissection in CTD. Given advances in cardiac surgery and 
increasing survival over the past several decades, there has been rising concern that, 
as patients who have survived surgical correction of these defects age, there may be 
increased morbidity and mortality due to aortic dissection and aortic regurgitation. This 
review discusses the most recent developments in research into AD in CTD, including 
associated genetic mutations.
Keywords: conotruncal, tetralogy of Fallot, transposition of great arteries, aortic aneurysm, aortic dissection, 
truncus arteriosus
inTRODUCTiOn
Conotruncal cardiac defects (CTDs) include a variety of congenital heart defects, such as tetralogy 
of Fallot (TOF), truncus arteriosus (TA), double outlet right ventricle (DORV), and transposition of 
the great arteries (TGA). These defects represent 5–10% of congenital heart disease and, generally, 
lead to severe cyanosis, necessitating repair in the newborn period or early in infancy. A common 
observation in CTD is thoracic aortic dilation (AD). It has been known for over half a century that 
AD is common in TOF (1, 2). Landmark work by Niwa demonstrated that the incidence of AD in 
adults with repaired tetralogy approaches 15% (3). Progressive dilation of the neo-aortic root is out 
of proportion to somatic growth in TGA after arterial switch surgery (4), and AD is found in the 
majority of patients with TA who survive initial repair (5).
Aortic dilation can become more clinically relevant if it leads to significant aortic valve regurgita-
tion, aortic dissection, or worsened LV–aorta interaction (6). AD can lead to significant morbidity 
and mortality, with the chief worry being ascending aortic or aortic root dissection, which is often 
fatal without emergency surgery, and as a result, clinicians seek to evaluate patients to avoid this 
complication, generally by assessing aortic size on non-invasive imaging, and intervening with 
elective surgery in a more controlled setting. Specific guidelines exist for elective surgery to prevent 
dissection in Marfan syndrome and certain other connective tissue disease, but specific guidelines 
Abbreviations: AD, aortic dilation; CTD, conotruncal defects; DORV, double outlet right ventricle; FBN1, fibrillin-1 gene; 
TGA, transposition of the great arteries; TOF, tetralogy of Fallot.
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for elective surgery for AD in CTD have not been established (7). 
One interesting article over several years evaluated the outcomes 
of 81 adults with CTD and AD who had surgery over several 
decades and came to the conclusion that elective surgery in CTD 
should be delayed unless the maximum aortic dimension is at 
least 5.5  cm, unless there is documented rapid growth of the 
ascending aorta, or a worrisome family history of aortic dissec-
tion or aneurysm (8).
In the past, it was thought that the risk of aortic dissection 
in these patients was low, perhaps due to the low incidence of 
systemic hypertension, smoking, and other traditional vascular 
risk factors in this population (9). However, there have now 
been four case reports of dissection in TOF (10–13). All these 
cases except the most recent one dissected at diameters >6 cm. 
Perhaps, aortic cannulation during the initial repair could be 
blamed for a dissection late after repair, but this seems unlikely 
given that the dissections occurred anywhere from 9 years to 
more than 30  years after the initial repair (10–13). It would 
stand to reason that, if direct injury to the aorta during initial 
cannulation was the culprit, there would be a significant number 
of dissections reported in childhood in the literature, when, in 
fact, the youngest patient identified in the literature was already 
18 years of age, more than 17 years after initial compete TOF 
repair (12).
Regarding TGA, fortunately, no case reports of aortic dissec-
tion in TGA after arterial switch have been published, but perhaps 
none have occurred due to the relative young age of this popula-
tion, given that most survivors of the arterial switch procedure 
are <30 years old. To date, there has only been one case report 
of an aortic dissection in TGA after Mustard repair (14). In this 
case, the patient had been lost to cardiology follow-up for over 
two decades, had several pregnancies, and smoked cigarettes, 
and it was unknown what size the aorta was prior to dissection. 
Isolated cases of dissection in CTD have also been found in 
review of administrative databases (15). There has been only one 
case report of elective aortic root replacement in a TGA patient 
after Mustard procedure – which was performed in a 30-year-old 
man, for an aortic aneurysm, measuring 4.5  cm (16). Still, the 
majority of patients with dissection in CTD have been older than 
45  years of age. However, as the population of CTD survivors’ 
ages, more patients might be at risk for aortic dissection or other 
complication.
It is important to note that aortic dissection is not the only 
concern or cause of morbidity due to AD in patients with CTD. 
The dilation itself can lead to significant aortic valve regurgitation, 
which can lead to an increased pulsatile load on the left ventricle 
(or systemic right ventricle), leading directly to decreased cardiac 
output, or indirectly via decreasing coronary arterial blood flow 
(17, 18). Aortic regurgitation may additionally worsen not just 
due to dilation but also due to stiffness of the aortic root (19). 
The need for aortic valve replacement is fortunately fairly uncom-
mon in CTD, although the presence of aortic regurgitation is 
fairly common in TGA after arterial switch (3, 20). After arterial 
switch surgery, Losay and others noted that freedom from aortic 
regurgitation was 78% at 10 years and 69% at 15 years; however, 
freedom from aortic valve replacement was 98% at 10 years and 
97% at 15  years (21). In a study by Marino and others, severe 
neo-aortic valve regurgitation was present in 3.7% and trivial to 
mild regurgitation in 81% of patients at mid-term follow-up (22).
POSSiBLe MeCHAniSMS  
FOR AORTiC ROOT DiLATiOn in  
COnOTRUnCAL DeFeCTS
There are a few hypotheses for why AD in CTD occurs, inde-
pendent of standard risk factors, such as hypertension, aging, 
pregnancy, and smoking. The first is that AD occurs due to 
hemodynamic stress on the aorta from a chronic right-left-
shunt. Evidence to support this hypothesis include data showing 
that AD is worse with worsened degrees of right ventricular 
outflow tract stenosis and is worse in patients with pulmonary 
atresia than in patients with pulmonary stenosis (23). A second 
hypothesis is that volume loading of the aorta, via a surgical 
systemic-to-pulmonary shunt, will increase flow through the 
aortic valve, thus leading to dilation of the proximal aorta via 
increased wall stress (24). A longer duration between shunting 
and complete repair has been found to correlate with AD in 
repaired TOF (23, 25). One study showed a 12% increase in 
mean aortic diameter after surgical aortopulmonary shunting 
(25). Other observations that have been associated with larger 
aortic dimensions in TOF have included a right rather than left 
aortic arch and male sex.
Newer data suggest that CTD may be associated with a 
primary problem with aortic histology, i.e., a true aortopathy. 
Evidence of aortopathy in TOF has been found early in life, on 
fetal echocardiography (26), and also on histologic studies. Even 
in infants, higher histologic grading scores in TOF patients have 
been seen, thus making it likely that there is an intrinsic abnor-
mality of the aortic tissue leading to dilation, rather than long-
term hemodynamic stress (20). Histologic abnormalities were 
reported in a cohort of 15 repaired TOF patients with ascending 
aortic aneurysms, and this was further supported in another 
study demonstrating elastin fragmentation in the ascending aorta 
in 74.5% of 98 consecutive patients undergoing complete TOF 
repair (27, 28).
There are many variables that affect the size of the aortic root 
and ascending aorta in general. Although there have been simi-
larities of aortic root histology seen between Marfan syndrome 
and some CTDs, it is notable that the risk of dissection in Marfan 
is significantly higher, which begs the question why the Marfan 
phenotype is so much more dangerous. It is possible that the 
histologic abnormality in the aorta found in TOF may be less 
severe than the abnormality found in Marfan syndrome (27).
Most research regarding AD in CTD predominantly focused 
on TOF with fewer papers focused on TGA or truncus. DORV 
is rarely considered by itself in the literature, as it is a diagnosis 
encompassing a broad spectrum of pathophysiology, depending 
on where the ventricular septal defect is in an individual patient 
and also on the relationship of the great arteries to one another. It 
most commonly presents with TOF-like physiology, wherein the 
patient has a subaortic ventricular septal defect with pulmonary 
stenosis. In most of the literature, DORV with this physiology is 
included as a TOF variant.
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Conclusions have been difficult to draw, given differing defini-
tions of what constitutes an aortic aneurysm. Most pediatric cent-
ers have used Z-scores, whereas most adult studies have looked at 
either absolute dimensions or dimensions indexed to either body 
surface area or height. A common definition for “aneurysm” is an 
observed to expected ratio of >1.5 of the normal population at a 
specific aortic segment. A large study using cardiac MRI evaluated 
normal values in a control population and can be used as a help-
ful baseline (29). Very few studies have performed longitudinal 
measurements to demonstrate if the AD found in CTD is likely 
to progress over time. In one study of children with both TOF 
and TGA, independent predictors of a longitudinal increase in 
Z-scores of the ascending aorta included male sex and presence of 
aortic regurgitation (30). A study of adults with repaired tetralogy, 
utilizing MRI as the imaging technique, showed minimal growth 
in TOF over the course of 3 years, with a very small number of 
aortas increasing in size from below to above a threshold value 
of 5 cm (31).
As survival of CTD patients has improved, numerous 
patients with CTD have been able to have pregnancies of their 
own. Pregnancy is known to be an independent variable for the 
structural change of the aortic media, but it is unknown how 
likely these changes are to regress after delivery and whether the 
changes that occur with gestation are additive to the normal aging 
process in this population (27).
GeneTiC AnD MOLeCULAR FinDinGS
The investigation of AD in CTD from a molecular and genetic 
standpoint, compared to the robust database found in Marfan 
syndrome, is still in its infancy. There have been very few articles 
investigating the genetic or histologic associations of AD and 
CTD, to date. Marfan syndrome, with a prevalence of 1:5000, is in 
most cases due to a mutation in the fibrillin-1 gene (FBN1) (32). 
Fibrillin-1, together with other proteins of the extracellular matrix, 
forms thread-like microfibrils, which create structural support 
and elasticity to tissues. Mutations in FBN1 lead to breakdown of 
microfibril architecture, which can lead to aortic aneurysms and 
other complications. There are numerous mutations in the FBN1 
mutation database, with nearly 3000 reported mutations to date, 
varying from point mutations to large rearrangements.
Research demonstrating that the histology of the aorta in 
patients with congenital heart disease is similar to that of Marfan 
patients (27) has led to small studies investigating the role of 
fibrillin in CTD. Given the much lower incidence of dissection 
in TOF, it is possible that the histologic abnormality in the aorta 
found in TOF may be less severe than the abnormality found 
in Marfan syndrome (27). In a study of 74 consecutive patients 
undergoing intracardiac repair or TOF, full-thickness aortic wall 
biopsies were performed, and there was a 50.9% prevalence of 
FBN1 gene polymorphisms or mutations in those with a dilated 
aorta (28). Additionally, the risk of AD was found to be eight 
times higher in patients with these variants. Abnormal histology, 
defined as a lamellar count <60, was associated with a risk of AD 
15.97 times higher than in normal controls.
The DiGeorge or velocardial facial syndrome, due to a 22q12 
deletion, is commonly associated with CTD, and 22q11.2 mutation 
has been found to be associated with larger aortic root size in TOF 
(33). Patients with 22q11.2 mutation are more likely to have right 
aortic arch and pulmonary atresia than non-syndromic patients, 
so it is unclear, in TOF, if the larger aortic size is due directly to 
the genetic mutation or rather due to a change in hemodynamics. 
However, one paper noted that the 22q11.2 deletion itself, even in 
the absence of CTD, appears to be associated with AD, where AD 
was noted to have an incidence of 10.8% (34).
Linkage analysis has been used to find novel gene mutations 
that appear to correlate with TOF and other CTD, but, to date, no 
studies have been performed to evaluate for novel mutations that 
explicitly explain AD in CTD.
It is possible that some of the patients in the literature who had 
CTD and aortic dissection may have had undiagnosed Marfan 
syndrome or other known connective tissue disease, as the lack 
of diagnosis may have been retrospectively made on phenotypic, 
rather than genotypic, grounds. There are numerous variables, 
including the underlying tissue strength, and varying changes in 
physiology that frustrate the ability to tease out.
FUTURe DiReCTiOnS
Further research into AD in CTD will be much more likely to 
proceed if more patients are found to suffer aortic complications. 
Next generation sequencing, such as whole exome sequencing, 
may be very helpful at identifying novel gene mutations that 
could be responsible for AD in CTD. Genome-wide linkage 
analysis and exome sequencing together, recently, led to the 
discovery of a novel TGFB3 mutation as a cause of syndromic 
aortic aneurysm and aortic dissection in series of 470 index 
cases with thoracic aortic aneurysms who had been screened 
for all known gene mutations associated with thoracic aortic 
aneurysms (35). Current standard genetic panels to test for 
aortopathy genes only include 20–25 gene mutations, but these 
panels will expand greatly as new candidate gene mutations are 
discovered. In silico analysis and more advanced informatics 
technology will greatly facilitate the ability to translate these 
findings to clinical practice.
SUMMARY
The American Heart Association (AHA) and American College 
of Cardiology (ACC) provide guidelines on the management of 
thoracic aortic diseases (7), but the most recent guidelines do 
not provide a clear management decision for how to manage AD 
in CTD patients. It is exceedingly rare for an aortic dissection 
to occur in childhood, other than in infancy, due to very severe 
genetic problems or iatrogenic causes; thus, aortic dissection 
is largely considered an adult-onset problem. The reader is 
directed to the current adult congenital heart disease clinical 
management guidelines (36), which are due for an update in 
the near future.
The decision of when to intervene for AD in CTD must be 
weighed on a number of factors, including the number of prior 
cardiac interventions (and thus, likelihood of morbidity of an 
elective procedure), the rate of growth of the aorta over time, 
other lesions that require operative management, and perhaps 
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most importantly, a genetic risk profile. For patients with a strong 
family history of thoracic aortic aneurysm, aortic dissection, or 
a known genetic mutation likely to lead to aortic dissection, 
perhaps, a lower threshold for intervention should be used.
Over time, we may discover advantages to elective aortic root 
replacement to improve LV–aorta coupling, even in patients 
not thought to be at acute risk of aortic dissection, as surgical 
techniques improve. Perhaps, newer discoveries will lead to new 
therapies that prevent, or even reverse, aortopathies.
Ultimately, only time will tell what the true risk for aortic 
complications in CTD is, and if the incidence grows over time 
as this population ages, more research will help determine who 
is at most risk. It is difficult to determine a risk profile when so 
few patients have had aortic complications. Ideally, in this era of 
personalized medicine and high throughput genetic sequencing, 
every patient will have a unique genetic signature that can be used 
to tailor his or her unique risk.
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